Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
Baxter
Moodys
Merck

Last Updated: October 1, 2022

TYSABRI Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Recent Clinical Trials for TYSABRI

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Queen Mary University of LondonPhase 2
Case Comprehensive Cancer CenterPhase 1/Phase 2
Vanderbilt University Medical CenterPhase 4

See all TYSABRI clinical trials

Recent Litigation for TYSABRI

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
Miltenyi Biomedicine GmbH2022-04-12
Swiss Pharma International AG2016-04-18

See all TYSABRI litigation

Pharmacology for TYSABRI
Mechanism of ActionIntegrin Receptor Antagonists
Established Pharmacologic ClassIntegrin Receptor Antagonist
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TYSABRI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TYSABRI Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Biogen Inc. TYSABRI natalizumab Injection 125104 See Plans and Pricing 2009-12-01 Company disclosures
Biogen Inc. TYSABRI natalizumab Injection 125104 See Plans and Pricing 2005-01-30 Company disclosures
Biogen Inc. TYSABRI natalizumab Injection 125104 See Plans and Pricing 2015-03-24 Company disclosures
Biogen Inc. TYSABRI natalizumab Injection 125104 See Plans and Pricing 2014-01-25 Company disclosures
Biogen Inc. TYSABRI natalizumab Injection 125104 See Plans and Pricing 2017-03-07 Company disclosures
Biogen Inc. TYSABRI natalizumab Injection 125104 See Plans and Pricing 2020-08-05 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for TYSABRI Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for TYSABRI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2006 00025 Denmark See Plans and Pricing PRODUCT NAME: NATALIZUMAB
C00804237/01 Switzerland See Plans and Pricing FORMER OWNER: ELAN PHARMACEUTICALS, INC., US
300240 Netherlands See Plans and Pricing PRODUCT: NATALIZUMAB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; FIRST REGISTRATION, DATE: EU/1/06/346/001, 20060627
SZ 27/2006 Austria See Plans and Pricing PRODUCT NAME: NATALIZUMAB
06C0024 France See Plans and Pricing PRODUCT NAME: NATALIZUMAB,ANTICORPS MONOCLONAL HUMANISE ANTI-INTEGRINE ALPHA-4; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
91273 Luxembourg See Plans and Pricing 91273, EXPIRES: 20150831
132006901441326 Italy See Plans and Pricing AUTHORISATION NUMBER(S) AND DATE(S): EU/1/06/346/001, 20060627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Johnson and Johnson
AstraZeneca
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.